Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




MRSA: What Do We Tell Our Patients about Institutional Precautions in the Presence of Conflicting Un
Link ID 4928
Title MRSA: What Do We Tell Our Patients about Institutional Precautions in the Presence of Conflicting Un
Url http://www.medscape.com/viewarticle/573003?src=rss
Description Dr. Paul Auwaerter discusses the challenges of current evidence when reviewing hospital acquired infection control and surveillance practices. What do you share with your patients who inquire?
Category Articles > Business of Medicine
Keywords
Date Apr 17, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. Coventry Health Profit up 3 Pct, Meets Estimates
  Coventry Health Care Inc posted a 3 percent first-quarter profit increase on Friday, matching Wall Street estimates, helped by higher membership, and the insurer backed its full-year forecast. Reuters Health Information
Category:   Articles > Business of Medicine


2. Pharmacogenetic Tests Lack Regulatory Oversight, Critics Say
  A new critique of the system says that misleading claims and lack of validation may endanger public attitudes toward personalized medicine. Medscape Medical News
Category:   Articles > Business of Medicine


3. Enabling Patients to Participate in Self-care Activities After Transferring From the Hospital to the
  The Care Transitions Intervention and the Care Transitions Measure -- currently the only measures of transitional care quality endorsed by the National Quality Forum. Medscape Internal Medicine
Category:   Articles > Business of Medicine


4. Health Net Profit Rises, but Forecast Is Weak
  Insurer Health Net Inc posted a 46 percent rise in quarterly profit Tuesday, helped by its Medicare plans for older Americans, but forecast 2008 earnings below Wall Street expectations. Reuters Health Information
Category:   Articles > Business of Medicine


5. FDA Reprimands GlaxoSmithKline Over Missing Data on Rosiglitazone
  In a letter to GlaxoSmithKline, the FDA said that an inspection in late 2007 focusing on compliance with postmarketing adverse drug experience reporting requirements found that the company failed to report data from clinical usage and failed to disclose or submit data from clinical trials. Heartwire
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS